Common questions about Eribulin (FAQ)
Q: Why is Eribulin sometimes referred to by its brand name, Halaven?
A: Eribulin is often referred to by the brand name Halaven. Halaven is the registered commercial name for the medicine that contains the active substance Eribulin mesylate. This is a common practice in medicine, where the generic name is the active substance and the brand name is the product's trademark.
Q: What is the typical duration of Eribulin-related fatigue or weakness?
A: Fatigue (asthenia) is listed in official documents as a very common side effect. Regulatory sources do not provide a specific timeline for how long this tiredness lasts. However, clinical information suggests that fatigue may continue for a period even after the treatment regimen is complete.
Q: What are the signs of a low white blood cell count related to Eribulin?
A: Eribulin treatment can be associated with severe neutropenia, which is a significant drop in infection-fighting white blood cells. Official regulatory documents advise that patients should be aware of signs such as fever or other indications of infection, as monitoring for these is necessary due to the risk of severe neutropenia (low white blood cell count).
Q: Is hair loss (alopecia) permanent after stopping Eribulin?
A: Hair loss, or alopecia, is a very common side effect noted in official product information. While the sources do not explicitly state if the hair loss is permanent, general patient information suggests that hair often begins to regrow after Eribulin therapy is discontinued.
Q: What common side effects of Eribulin are generally described as "manageable"?
A: The drug's safety profile, based on regulatory data, documents common adverse reactions such as fatigue, nausea, and peripheral neuropathy. These events are often described in trials as mild-to-moderate (Grade 1 or 2), which suggests they are often addressed with supportive care.
Q: What are the signs of a mineral or electrolyte imbalance that may be caused by Eribulin?
A: Eribulin has been associated with imbalances, specifically low potassium (hypokalemia) and low magnesium (hypomagnesemia). Official documents advise that these imbalances are typically corrected before starting therapy because they can increase the risk of serious heart rhythm changes, even if the specific symptoms of the imbalance are not detailed.
Q: Is joint or muscle pain a known side effect of Eribulin?
A: Yes, both joint pain (arthralgia) and muscle pain (myalgia) are reported as common side effects in the official regulatory documents for Eribulin.
Q: Can Eribulin cause changes in taste or loss of appetite?
A: Changes in taste, known as dysgeusia, and a loss of appetite, or anorexia, are listed as common side effects in the official product information for Eribulin.
Q: Are there any known lung problems or breathing issues associated with Eribulin?
A: Official product information reports common respiratory side effects such as cough and dyspnea (shortness of breath). These effects, if they occur, are typically managed by a healthcare provider.
Q: Is it true that Eribulin can cause dizziness or vertigo?
A: Yes, dizziness is listed as a common side effect of Eribulin in regulatory documents. This type of effect is documented under the nervous system disorders.
Q: How long after the last infusion do people typically see improvement in numbness and tingling?
A: Peripheral neuropathy (numbness and tingling) is a common side effect that may be linked to the total amount of drug received over time. Regulatory documents indicate that while symptoms may slowly lessen after treatment is stopped, neuropathy has been noted to persist for an extended duration in certain instances.
Q: Are there any specific non-prescription supplements that should be avoided with Eribulin?
A: Official product information states that concomitant use of St John’s wort is not recommended. This is because this non-prescription supplement may potentially reduce the amount of Eribulin in the body.
Q: Is it necessary to limit alcohol intake while on Eribulin?
A: The Eribulin solution does contain a very small amount of ethanol (alcohol) in its formulation. However, official regulatory documents state that the amount of alcohol present is generally too small to have any noticeable or relevant effect.
Q: What is the recommended period for women to use contraception after stopping Eribulin?
A: Official information advises that females who can become pregnant should use effective birth control throughout the treatment period. This effective contraception should be continued for at least 2 weeks following the final dose of Eribulin.
Q: What is the recommended period for men to use contraception after stopping Eribulin?
A: Official information advises that males with female partners who can become pregnant should use effective birth control throughout the treatment period. This effective contraception should be continued for 3.5 months following the last dose of Eribulin.
Q: How soon after starting treatment might a patient notice any effect, based on research themes?
A: Official clinical trial data provides a measure of how long patients in the study lived without their disease worsening (Progression-Free Survival, or PFS). For example, the median PFS in the key metastatic breast cancer trial was reported as 3.7 months.
Q: Is there ongoing research into new uses for Eribulin?
A: Yes, official summaries and publicly available databases indicate that Eribulin continues to be investigated. Ongoing clinical studies are examining its use in various cancer types, different combination therapies, and alternative dosing approaches.
Q: Why is Eribulin sometimes discussed in the context of different dosing standards (mg vs mg/m2)?
A: The dose is precisely calculated based on the individual's body surface area ( mg/m^2). The differences in dose numbers, such as 1.4 mg/m^2 versus 1.23 mg/m^2, are due to the use of different regulatory reference standards—one referring to the mesylate salt basis and the other to the eribulin base.
Q: Does Eribulin have any potential effects on the kidneys?
A: Official product information indicates that Eribulin exposure in the body is higher for patients with moderate or severe kidney (renal) impairment. Due to this finding, which may require a lower initial starting dose as determined by a healthcare provider.
Q: What makes a patient generally eligible for Eribulin treatment for metastatic breast cancer?
A: According to official regulatory documents, eligibility for metastatic breast cancer ( mBC) is generally defined as patients who have previously received chemotherapy. This prior treatment typically includes an anthracycline and a taxane, unless those therapies were deemed unsuitable.
Q: Is Eribulin used to treat all types of liposarcoma?
A: Official labeling indicates Eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. The treatment is approved for this general population based on clinical trial evidence.
Q: What is the reported average difference in overall survival for Eribulin vs. comparison drugs in clinical studies?
A: Studies and official documents quantify the effect in clinical trials. For example, in the Phase 3 EMBRACE trial for metastatic breast cancer, the median Overall Survival ( OS) was reported as 13.1 months in the Eribulin group versus 10.6 months in the control group.
Q: What are the reasons why a doctor might need to delay an Eribulin dose?
A: Official product information states that a dose may need to be delayed in certain circumstances. Specifically, the Day 8 dose may be postponed for up to a week if the patient is experiencing specific toxicities, particularly if blood cell counts (like neutrophils or platelets) are lower than required thresholds.
